Lauren Carter

List of Publications by Citations

39 papers	2,290 citations	16 h-index	47 g-index
47 ext. papers	3,839 ext. citations	26.4 avg, IF	4.9 L-index

#	Paper	IF	Citations
39	Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19. *Cell*, **2021**, 184, 169-183.e17	56.2	327
38	Global analysis of protein folding using massively parallel design, synthesis, and testing. *Science*, **2017**, 357, 168-175	33.3	241
37	Massively parallel de novo protein design for targeted therapeutics. *Nature*, **2017**, 550, 74-79	50.4	235
36	De novo design of picomolar SARS-CoV-2 miniprotein inhibitors. *Science*, **2020**, 370, 426-431	33.3	219
35	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. *Cell*, **2020**, 183, 1367-1382.e17	56.2	217
34	Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus. *Cell*, **2019**, 176, 1420-1431.e17	56.2	190
33	De novo design of potent and selective mimics of IL-2 and IL-15. *Nature*, **2019**, 565, 186-191	50.4	184
32	De novo design of a fluorescence-activating β barrel. *Nature*, **2018**, 561, 485-491	50.4	156
31	Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. *Nature*, **2021**, 594, 253-258	50.4	92
30	Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants. *Science*, **2021**, eabl8506	33.3	65
29	De novo design of a non-local β-sheet protein with high stability and accuracy. *Nature Structural and Molecular Biology*, **2018**, 25, 1028-1034	17.6	54
28	Quadrivalent influenza nanoparticle vaccines induce broad protection. *Nature*, **2021**, 592, 623-628	50.4	40
27	A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response. *PLoS Pathogens*, **2016**, 12, e1005409	7.6	36
26	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. *Cell*, **2021**, 184, 5432-5447.e16	56.2	34
25	De novo protein design by deep network hallucination. *Nature*, **2021**,	50.4	33
24	F-domain valency determines outcome of signaling through the angiopoietin pathway **2020**,		28
23	Engineered SARS-CoV-2 receptor binding domain improves manufacturability in yeast and immunogenicity in mice. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	13

22	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines **2021**,		12
21	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. *Cell Host and Microbe*, **2021**, 29, 1151-1161.e5	23.4	11
20	Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2 **2020**,		10
19	Engineered SARS-CoV-2 receptor binding domain improves immunogenicity in mice and elicits protective immunity in hamsters **2021**,		10
18	In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19. *Scientific Reports*, **2021**, 11, 4290	4.9	9
17	Computational design of a synthetic PD-1 agonist. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	9
16	Functional SARS-CoV-2-specific immune memory persists after mild COVID-19 **2020**,		7
15	Incorporation of sensing modalities into de novo designed fluorescence-activating proteins. *Nature Communications*, **2021**, 12, 856	17.4	7
14	Structure-based Design of JOC-x, a Conjugatable Tumor Tight Junction Opener to Enhance Cancer Therapy. *Scientific Reports*, **2019**, 9, 6169	4.9	6
13	Characterizing protein G B1 orientation and its effect on immunoglobulin G antibody binding using XPS, ToF-SIMS, and quartz crystal microbalance with dissipation monitoring. *Biointerphases*, **2020**, 15, 021002	1.8	6
12	F-domain valency determines outcome of signaling through the angiopoietin pathway. *EMBO Reports*, **2021**, 22, e53471	6.5	4
11	Sampling of Structure and Sequence Space of Small Protein Folds		4
10	SARS-COV-2 spike binding to ACE2 in living cells monitored by TR-FRET. *Cell Chemical Biology*, **2021**,	8.2	4
9	Multivalent designed proteins protect against SARS-CoV-2 variants of concern **2021**,		4
8	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. *Science Immunology*, **2022**, 7,	28	3
7	Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination. *JCI Insight*, **2021**, 6,	9.9	3
6	Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice.. *Science Translational Medicine*, **2022**, 14, eabn1252	17.5	3
5	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples. *Journal of Immunological Methods*, **2021**, 499, 113160	2.5	2

4	High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells.. *Science Immunology*, **2021**, eabl5652	28	2
3	Ultrapotent miniproteins targeting the receptor-binding domain protect against SARS-CoV-2 infection and disease in mice **2021**,		1
2	Detection of antibodies neutralizing historical and emerging SARS-CoV-2 strains using a thermodynamically coupled de novo biosensor system **2021**,		1
1	Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples **2021**,		1